🇪🇺 Veozah in European Union

EMA authorised Veozah on 7 December 2023

Marketing authorisation

EMA — authorised 7 December 2023

  • Application: EMEA/H/C/005851
  • Marketing authorisation holder: Astellas Pharma Europe B.V.
  • Local brand name: Veoza
  • Indication: Veoza is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
  • Status: approved

Read official source →

Veozah in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Neuroscience approved in European Union

Frequently asked questions

Is Veozah approved in European Union?

Yes. EMA authorised it on 7 December 2023.

Who is the marketing authorisation holder for Veozah in European Union?

Astellas Pharma Europe B.V. holds the EU marketing authorisation.